Abstract
Gastroesophageal reflux (GER), commonly diagnosed in preterm infants in neonatal intensive care units (NICUs), is a cause of morbidity and is known to prolong hospital stay. Pharmacological treatment of presumed or proven GER is increasingly being used in NICUs; this attitude is concerning, owing to an association between pharmacological treatment of GER and serious adverse events, which has recently been demonstrated (i.e., ranitidine and necrotizing enterocolitis). Furthermore, a wide variability exists among NICUs in the proportion of infants treated for GER, which suggests a serious lack of evidence in this field. Thus, there is a need to develop safe and effective treatment options for GER in preterm infants is a critical issue for future research.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
